Technetium tc 99m tilmanocept
As of the edition of 20 October 2026, Technetium tc 99m tilmanocept is a protein: marketed, first approved in 2013 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Protein
- Brand name
- Lymphoseek Kit
- First approved
- 13 March 2013 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Cardinal Health 414 Llc Cardinal Health Nuclear Pharmacy
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Cardinal Health 414 Llc Cardinal Health Nuclear Pharmacy | Acquired holder | 2017 to now |
| Navidea Biopharmaceuticals | Originator | 2013 to 2017 |